CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00167310

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:36.675565+00:00

Published At

2017-04-10T00:00:00+00:00

Record Updated At

2017-04-10

Results Posted At

2017-04-10

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Schizophrenia", "Schizoaffective Disorder", "Major Depression", "Bipolar Disorder", "Coronary Artery Disease"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2017-04-10"

protocolSection.identificationModule.nctId

"NCT00167310"

protocolSection.identificationModule.officialTitle

"CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2017-04-10"

Study condition terms

• Schizophrenia (protocolSection.conditionsModule.conditions)
• Schizoaffective Disorder (protocolSection.conditionsModule.conditions)
• Major Depression (protocolSection.conditionsModule.conditions)
• Bipolar Disorder (protocolSection.conditionsModule.conditions)
• Coronary Artery Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.